<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Evaluation and management of patients with acute decompensated heart failure: HFSA 2010 comprehensive heart failure practice guideline.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. Evaluation and management of patients with acute decompensated heart failure: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010 Jun;16(6):e134-56. [145 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail 2006 Feb;12(1):e86-103.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Congestive heart failure, unspecified  (428.0); Heart failure, unspecified  (428.9); Renal failure, unspecified  (586)"/><FieldValue Value="MSH: Anticoagulants ; Body Weight ; Cardiac Catheterization ; Cardiotonic Agents ; Continuous Positive Airway Pressure ; Diet, Sodium-Restricted ; Diuretics ; Heart Failure ; Hemodynamics ; Hemofiltration ; Heparin ; Heparin, Low-Molecular-Weight ; Hospitalization ; Kidney Function Tests ; Natriuretic Peptide, Brain ; Nitroglycerin ; Nitroprusside ; Oxygen Inhalation Therapy ; Patient Discharge ; Polysaccharides ; Vasodilator Agents ; Vital Signs "/><FieldValue Value="MTH: Anticoagulants ; Body Weight ; Cardiac Catheterization Procedures ; Cardiotonic Agents ; Congestive heart failure ; Continuous Positive Airway Pressure ; Discharge Planning ; Fluid output ; Heart failure ; Hemodynamics ; Heparin ; Heparin, Low-Molecular-Weight ; Hospitalization ; KIDNEY FAILURE ; Kidney Function Tests ; Loop Diuretics ; Low sodium diet ; Measure of fluid intake ; NATRIURETIC PEPTIDE TEST DEVICE ; Nesiritide ; Nitroglycerin ; Oxygen Therapy Care ; Patient Discharge ; Polysaccharides ; Positive End-Expiratory Pressure ; Vasodilator Agents ; Vital signs "/><FieldValue Value="PDQ: heparin ; nesiritide ; renal failure "/><FieldValue Value="SNOMEDCT_US: Acute heart failure  (56675007); Anticoagulant  (372862008); Anticoagulant  (81839001); Body weight  (27113001); Body weight measure  (363808001); Cardiac catheterization  (41976001); Cardiotonic drug  (69440003); Congestive heart failure  (42343007); Continuous positive airway pressure ventilation treatment  (47545007); Discharge planning  (371754007); Diuretic  (30492008); Diuretic  (372695000); Electrolytes measurement  (79301008); Fluid output  (251840008); Fluid restriction  (25389001); Fondaparinux  (395236007); Fondaparinux  (708189008); Heart failure  (84114007); Hemofiltration  (233581009); Heparin  (372877000); Heparin  (84812008); Heparin  (96382006); Inotropic agent  (111139005); Inotropic agent  (373213009); Inpatient care  (394656005); Loop diuretic  (29051009); Loop diuretic  (372691009); Low molecular weight heparin  (373294004); Low molecular weight heparin  (87233003); Low sodium diet  (386619000); Low sodium diet  (437421000124105); Measure of fluid intake  (364399002); Nesiritide  (385678006); Nesiritide  (385679003); Nesiritide  (385680000); Nesiritide  (407059007); Nitroglycerin  (387404004); Nitroglycerin  (71759000); Nitroprusside  (372860000); Nitroprusside  (8163008); Oxygen therapy  (57485005); Patient discharge  (58000006); Plasma B natriuretic peptide measurement  (412905009); Plasma pro-brain natriuretic peptide level  (408258008); Polysaccharide  (71544008); Renal failure syndrome  (42399005); Renal function study  (44277000); Vasodilating agent  (372787008); Vasodilating agent  (58944007); Vital signs  (46680005)"/><FieldValue Value="SPN: HEPARIN ; TEST,NATRIURETIC PEPTIDE "/><FieldValue Value="UMD: Positive Airway Pressure Units  (20-742)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Acute decompensated heart failure (ADHF)&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: ADHF can include worsening renal function, persistent neurohormonal activation, and progressive deterioration in myocardial function. Decompensation also commonly occurs without a fundamental worsening of underlying cardiac structure or function.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Critical Care" /><FieldValue Value="Emergency Medicine" /><FieldValue Value="Internal Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Emergency Medical Technicians/Paramedics" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To provide recommendations for the evaluation and management of patients with acute decompensated heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To update and expand the previous 2006 clinical practice guidelines &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with acute decompensated heart failure (ADHF)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Evaluation of signs and symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Determination of plasma B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) when necessary &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospital admission, as indicated, and careful monitoring of weight, fluid intake and output, vital signs, other signs and symptoms, electrolytes, and renal function &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Loop diuretics &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Careful observation for the development of renal dysfunction and other side effects &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sodium and fluid restriction, increased doses of loop diuretics, continuous infusion of a loop diuretic, addition of a second type of diuretic orally or intravenously, or ultrafiltration, if needed &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Supplemental oxygen, in presence of hypoxia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-invasive positive pressure ventilation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low dose unfractionated heparin (UF), low molecular weight heparin LMWH), or fondaparinux &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intravenous vasodilators &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intravenous inotropes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Invasive hemodynamic monitoring in specific patients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluation of admitted patients for precipitating factors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Discharge planning &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity and specificity of diagnostic tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospitalization rate&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Survival rate&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A literature search with relevant key words and phrases for each guideline section were provided to members of the subcommittees and the full Guideline Committee. Members of each subcommittee were asked to review the search and identify any additional relevant medical evidence for each assigned section.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following databases were searched:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Ovid Medline (1950 to the updated date when the search was conducted) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ovid Medline In-Process and other Non-Indexed Citations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PubMed &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The searches focused primarily on the period between the last guideline publication and current, although the authors went back to 2005 to account for publication lag between the completion of the guideline and its publication in 2006 (i.e., 2005&amp;ndash;2010) in the event there was some information that should/could be added to the 2010 updated document. Generally only non-human studies and publications that were non-English were excluded.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following search terms were used: Heart failure; epidemiology; hospitalization; vital statistics; morbidity; mortality; cardiac output, low; natriuretic peptide, brain; dyspnea; ultrafiltration; diuretics; vasodilator agents; dobutamine; phosphodiesterase inhibitors; nitrates; hemodynamics.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Hierarchy of Types of Evidence&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Hierarchy of Types of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized, Controlled, Clinical Trials&lt;br /&gt;&#xD;&#xA;            May be assigned based on results of a single methodologically rigorous trial&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Cohort and Case-Control Studies&lt;br /&gt;&#xD;&#xA;            Post hoc, subgroup analysis, and meta-analysis&lt;br /&gt;&#xD;&#xA;            Prospective observational studies or registries&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert Opinion&lt;br /&gt;&#xD;&#xA;            Observational studies &amp;ndash; epidemiologic findings&lt;br /&gt;&#xD;&#xA;            Safety reporting from large-scale use in practice&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Heart Failure Society of America (HFSA) Guideline Approach to Medical Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two considerations are critical in the development of practice guidelines: assessing strength of evidence and determining strength of recommendation. Strength of evidence is determined both by the type of evidence available and the assessment of validity, applicability, and certainty of a specific type of evidence. Following the lead of previous guidelines, strength of evidence in this guideline is heavily dependent on the source or type of evidence used. The HFSA guideline process has used three grades (A, B, or C) to characterize the type of evidence available to support specific recommendations (see Table 1.2 in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;HFSA Guideline Approach to Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Determining Strength. Although level of evidence is important, the strength given to specific recommendations is critical. The process used to determine the strength of individual recommendations is complex. The goal of guideline development is to achieve the best recommendations for evaluation and management, considering not only efficacy, but the cost, convenience, side effect profile, and safety of various therapeutic approaches. The HFSA guideline committee often determined the strength of a recommendation by the &quot;totality of evidence,&quot; which is a synthesis of all types of available data, pro and con, about a particular therapeutic option. The HFSA guideline employs the categorization for strength of recommendation outlined in Table 1.3 in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Process of Guideline Development&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Key steps in the development of this guideline are listed in Table 1.4 in the original guideline document. Having determined the broad scope of the current guideline, subcommittees of the guideline committee were formed for each section of the guideline. A literature search with relevant key words and phrases for each guideline section were provided to members of the subcommittees and the full Guideline Committee. Members of each subcommittee were asked to review the search and identify any additional relevant medical evidence for each assigned section. Changes in recommendation and background were carried out by each subcommittee with conference calls directed by the Guideline Committee chair. Each section was presented for comments and consensus approval to the Guideline Committee. Once subsections were complete, the Executive Council reviewed and commented on each section and these comments were returned to the Guideline Committee for changes and once complete, for final approval by the Executive Council.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Consensus&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Heart Failure Society of America (HFSA) Guideline Committee sought resolution of difficult cases through consensus building. An open, dynamic discussion meant that no single voice was allowed to dominate. Written documents were essential to this process, because they provided the opportunity for feedback from all members of the group. On occasion, consensus of opinion was sufficient to override positive or negative results of almost any form of evidence. The HFSA process had a strong commitment to recommendations based on objective evidence rigorously reviewed by a panel of experts. Issues that caused difficulty for the HFSA guideline process were some of the more important ones faced by the committee, because they mirrored those that are often most challenging to clinicians in day-to-day practice. The foundation of the HFSA guideline process was the belief that the careful judgment of recognized opinion leaders in these controversial areas is more likely to be correct than ad hoc decisions made &quot;on the spot&quot; by physicians in practice.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Classifying the Strength of the Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Classifying the Strength of the Recommendations&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Part of routine care&lt;br /&gt;&#xD;&#xA;            Exceptions to therapy should be minimized. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Should be considered&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Majority of patients should receive the intervention.&lt;br /&gt;&#xD;&#xA;            Some discretion in application to individual patients should be allowed.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;May be considered&quot; &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Individualization of therapy is indicated.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is not recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Therapeutic intervention should not be used&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The large direct costs associated with caring for the 5 million Americans who have chronic heart failure (HF) are largely attributable to hospitalization. Alternatively, those patients with acute decompensated heart failure (ADHF) without obvious high-risk features may benefit from further treatment and risk-stratification in an observation unit (OU). OU management has been suggested to be a safe and cost-effective alternative to hospitalization in specific subsets of patients.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Also, hospital admission provides the opportunity to educate patients concerning their HF and to reinforce both pharmacologic and non-pharmacologic approaches to management. Establishing support systems for patients with financial constraints is critical to their ability to obtain prescribed medications and access follow-up care. In a randomized, controlled trial of 233 hospitalized HF patients, a 1-hour pre-discharge teaching session directed by a nurse educator improved clinical outcomes and reduced cost of care.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Each section was presented for comments and consensus approval to the Guideline Committee. Once subsections were complete, the Executive Council reviewed and commented on each section and these comments were returned to the Guideline Committee for changes and once complete, for final approval by the Executive Council.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The strength of evidence (A, B, C) and strength of recommendations are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diagnosis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The diagnosis of acute decompensated heart failure (ADHF) should be based primarily on signs and symptoms. (Strength of Evidence = C)&#xD;&#xA;    &lt;p&gt;When the diagnosis is uncertain, determination of plasma B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration is recommended in patients being evaluated for dyspnea who have signs and symptoms compatible with heart failure (HF). (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;The natriuretic peptide concentration should not be interpreted in isolation, but in the context of all available clinical data bearing on the diagnosis of HF, and with the knowledge of cardiac and non-cardiac factors that can raise or lower natriuretic peptide levels.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Hospital Admission&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;Hospital admission is recommended for patients presenting with ADHF when the clinical circumstances listed in Table 1 (a), below, are present. Patients presenting with ADHF should be considered for hospital admission when the clinical circumstances listed in Table 1 (b) below, are present. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 1. Recommendations for Hospitalizing Patients Presenting with ADHF&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Recommendations for Hospitalizing Patients Presenting with ADHF&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Recommendation&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Clinical Circumstances&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;(a) Hospitalization Recommended&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Evidence of severely decompensated heart failure (HF), including:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Hypotension &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Worsening renal function &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Altered mentation &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Dyspnea at rest&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Typically reflected by resting tachypnea &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Less commonly reflected by oxygen saturation &amp;lt;90% &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Hemodynamically significant arrhythmia&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Including new onset of rapid atrial fibrillation &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Acute coronary syndromes &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;(b) Hospitalization Should be Considered&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Worsened congestion&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Even without dyspnea &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Signs and symptoms of pulmonary or systemic congestion&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Even in the absence of weight gain &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Major electrolyte disturbance &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Associated comorbid conditions&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Pneumonia &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Pulmonary embolus &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Diabetic ketoacidosis &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Symptoms suggestive of transient ischemic accident or stroke &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Repeated implantable cardioverter defibrillators (ICD) firings &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Previously undiagnosed HF with signs and symptoms of systemic or pulmonary congestion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 2. Signs and Symptoms of Congestion in Heart Failure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Signs and Symptoms of Congestion in HF&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Pulmonary&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Systemic&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Symptoms&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Dyspnea&lt;br /&gt;&#xD;&#xA;            Orthopnea&lt;br /&gt;&#xD;&#xA;            Paroxysmal nocturnal dyspnea (PND)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Edema&lt;br /&gt;&#xD;&#xA;            Abdominal (or hepatic) swelling and pain&lt;br /&gt;&#xD;&#xA;            Anorexia&lt;br /&gt;&#xD;&#xA;            Early satiety&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Signs&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Rales&lt;br /&gt;&#xD;&#xA;            Wheezing&lt;br /&gt;&#xD;&#xA;            Pleural effusion and tenderness&lt;br /&gt;&#xD;&#xA;            Hypoxemia&lt;br /&gt;&#xD;&#xA;            Third heart sound (left-sided)*&lt;br /&gt;&#xD;&#xA;            Worsening mitral regurgitation&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Edema&lt;br /&gt;&#xD;&#xA;            Elevated jugular venous pressure (JVP)&lt;br /&gt;&#xD;&#xA;            Hepatic enlargement&lt;br /&gt;&#xD;&#xA;            Ascites&lt;br /&gt;&#xD;&#xA;            Third heart sound (right-sided)*&lt;br /&gt;&#xD;&#xA;            Worsening tricuspid regurgitation &lt;br /&gt;&#xD;&#xA;            Hepatojugular reflux &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;* May occur without congestion&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that patients admitted with ADHF be treated to achieve the goals listed in the Table 3 below. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 3. Treatment Goals for Patients Admitted for Acute Decompensated Heart Failure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 12.3: Treatment Goals for Patients Admitted for ADHF&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Improve symptoms, especially congestion and low-output symptoms &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Restore normal oxygenation &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Optimize volume status &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Identify etiology (see &quot;Table: Initial Evaluation of Patients with a Diagnosis of HF&quot; in the National Guideline Clearinghouse [NGC] summary of the Heart Failure Society of American [HFSA] guideline &lt;a href=&quot;/content.aspx?id=23900&quot; title=&quot;Guideline #7983&quot;&gt;Evaluation of Patients for Ventricular Dysfunction and Heart Failure&lt;/a&gt;) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Identify and address precipitating factors &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Optimize chronic oral therapy &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Minimize side effects &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Identify patients who might benefit from revascularization &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Identify patients who might benefit from device therapy &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Identify risk of thromboembolism and need for anticoagulation therapy &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Educate patients concerning medications and self management of HF &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Consider and, where possible, initiate a disease management program &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients admitted with ADHF should be carefully monitored. It is recommended that the items listed in Table 4 below be assessed at the stated frequencies. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 4. Monitoring Recommendations for Patients Hospitalized With ADHF&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Monitoring Recommendations for Patients Hospitalized With ADHF&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Frequency&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Value&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Specifics&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least daily&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weight&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Determine after voiding in the morning &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Account for possible increased food intake due to improved appetite &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least daily&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fluid intake and output&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;More than daily&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Vital signs&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Orthostatic blood pressure if indicated &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Oxygen saturation daily until stable &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least daily&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Signs&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Edema &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Ascites &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Pulmonary rales &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Hepatomegaly &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Increased jugular venous pressure (JVP) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Hepatojugular reflux &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Liver tenderness &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least daily&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Symptoms&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Orthopnea &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Paroxysmal nocturnal dyspnea (PND) or cough &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Nocturnal cough &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Dyspnea &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Fatigue, lightheadedness &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least daily&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Electrolytes&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Potassium &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Sodium &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least daily&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Renal function&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Blood urea nitrogen (BUN) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Serum creatinine* &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*See background section in the original guideline document for additional recommendations on laboratory evaluations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Fluid Overload&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that patients admitted with ADHF and evidence of fluid overload be treated initially with loop diuretics&amp;mdash;usually given intravenously rather than orally. (Strength of Evidence = B) Ultrafiltration may be considered in lieu of diuretics. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that diuretics be administered at doses needed to produce a rate of diuresis sufficient to achieve optimal volume status with relief of signs and symptoms of congestion (edema, elevated JVP, dyspnea), without inducing an excessively rapid reduction in 1) intravascular volume, which may result in symptomatic hypotension and/or worsening renal function, or 2) serum electrolytes, which may precipitate arrhythmias or muscle cramps. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Careful repeated assessment of signs and symptoms of congestion and changes in body weight is recommended, because clinical experience suggests it is difficult to determine that congestion has been adequately treated in many patients. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring of daily weights, intake, and output is recommended to assess clinical efficacy of diuretic therapy. Routine use of a Foley catheter is not recommended for monitoring volume status. However, placement of a catheter is recommended when close monitoring of urine output is needed or if a bladder outlet obstruction is suspected of contributing to worsening renal function. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Careful observation for development of a variety of side effects, including renal dysfunction, electrolyte abnormalities, symptomatic hypotension, and gout is recommended in patients treated with diuretics, especially when used at high doses and in combination. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response. (Strength of Evidence = C) It is recommended that serum potassium and magnesium levels be monitored at least daily and maintained in the normal range. More frequent monitoring may be necessary when diuresis is rapid. (Strength of Evidence = C) Overly rapid diuresis may be associated with severe muscle cramps. If indicated, treatment with potassium replacement is recommended. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Careful observation for the development of renal dysfunction is recommended in patients treated with diuretics. Patients with moderate to severe renal dysfunction and evidence of fluid retention should continue to be treated with diuretics. In the presence of severe fluid overload, renal dysfunction may improve with diuresis. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When congestion fails to improve in response to diuretic therapy, the following options should be considered:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Re-evaluating presence/absence of congestion &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Sodium and fluid restriction &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Increasing doses of loop diuretic &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Continuous infusion of a loop diuretic &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Addition of a second type of diuretic orally (metolazone or spironolactone) or intravenously (chlorothiazide). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Another option, ultrafiltration, may be considered. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A low sodium diet (2 g daily) is recommended for most hospitalized patients (Strength of Evidence = C) In patients with recurrent or refractory volume overload, stricter sodium restriction may be considered. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fluid restriction (&amp;lt;2 L/day) is recommended in patients with moderate hyponatremia (serum sodium &amp;lt;130 mEq/L) and should be considered to assist in treatment of fluid overload in other patients. (Strength of Evidence = C) In patients with severe (serum sodium &amp;lt;125 mEq/L) or worsening hyponatremia, stricter fluid restriction may be considered. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine administration of supplemental oxygen in the presence of hypoxia is recommended. (Strength of Evidence = C) Routine administration of supplemental oxygen in the absence of hypoxia is not recommended. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of non-invasive positive pressure ventilation may be considered for severely dyspneic patients with clinical evidence of pulmonary edema. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Prevention of Deep Venous Thrombosis and Pulmonary Embolism&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;16&quot;&gt;&#xD;&#xA;    &lt;li&gt;Venous thromboembolism prophylaxis with low dose unfractionated heparin (UFH), low molecular weight heparin (LMWH), or fondaparinux to prevent proximal deep venous thrombosis (DVT) and pulmonary embolism (PE) is recommended for patients who are admitted to the hospital with ADHF and who are not already anticoagulated and have no contraindication to anticoagulation. (Strength of Evidence = B) Venous thromboembolism prophylaxis with a mechanical device (intermittent pneumatic compression devices or graded compression stockings) to prevent proximal DVT and PE should be considered for patients who are admitted to the hospital with ADHF and who are not already anticoagulated and who have a contraindication to anticoagulation. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Intravenous Vasodilators&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;17&quot;&gt;&#xD;&#xA;    &lt;li&gt;In the absence of symptomatic hypotension, intravenous nitroglycerin, nitroprusside or nesiritide may be considered as an addition to diuretic therapy for rapid improvement of congestive symptoms in patients admitted with ADHF. (Strength of Evidence = B) Frequent blood pressure monitoring is recommended with these agents. (Strength of Evidence = B) These agents should be decreased in dosage or discontinued if symptomatic hypotension or worsening renal function develops. (Strength of Evidence = B). Reintroduction in increasing doses may be considered once symptomatic hypotension is resolved. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intravenous vasodilators (nitroglycerin or nitroprusside) and diuretics are recommended for rapid symptom relief in patients with acute pulmonary edema or severe hypertension. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intravenous vasodilators (nitroprusside, nitroglycerin, or nesiritide) may be considered in patients with ADHF who have persistent severe HF despite aggressive treatment with diuretics and standard oral therapies.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Nitroprusside (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Nitroglycerine, nesiritide (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intravenous inotropes (milrinone or dobutamine) may be considered to relieve symptoms and improve end-organ function in patients with advanced HF characterized by left ventricular (LV) dilation, reduced left ventricular ejection fraction (LVEF), and diminished peripheral perfusion or end-organ dysfunction (low output syndrome), particularly if these patients have marginal systolic blood pressure (&amp;lt;90 mm Hg), have symptomatic hypotension despite adequate filling pressure, or are unresponsive to, or intolerant of, intravenous vasodilators. (Strength of Evidence = C)&#xD;&#xA;    &lt;p&gt;These agents may be considered in similar patients with evidence of fluid overload if they respond poorly to intravenous diuretics or manifest diminished or worsening renal function. (Strength of Evidence = C)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;When adjunctive therapy is needed in other patients with ADHF, administration of vasodilators should be considered instead of intravenous inotropes (milrinone or dobutamine). (Strength of Evidence = C)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Intravenous inotropes (milrinone or dobutamine) are not recommended unless left heart filling pressures are known to be elevated or cardiac index is severely impaired based on direct measurement or clear clinical signs. (Strength of Evidence = C)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;It is recommended that administration of intravenous inotropes (milrinone or dobutamine) in the setting of ADHF should be accompanied by continuous or frequent blood pressure monitoring and continuous monitoring of cardiac rhythm. (Strength of Evidence = C)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;If symptomatic hypotension or worsening tachyarrhythmias develop during administration of these agents, discontinuation or dose reduction should be considered. (Strength of Evidence = C)&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Hemodynamic Monitoring&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;21&quot;&gt;&#xD;&#xA;    &lt;li&gt;The routine use of invasive hemodynamic monitoring in patients with ADHF is not recommended. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Invasive hemodynamic monitoring should be considered in a patient:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Who is refractory to initial therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Whose volume status and cardiac filling pressures are unclear, &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Who has clinically significant hypotension (typically systolic blood pressure [SBP] &amp;lt;80mm Hg) or worsening renal function during therapy, or &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Who is being considered for cardiac transplant and needs assessment of degree and reversibility of pulmonary hypertension, or &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;In whom documentation of an adequate hemodynamic response to the inotropic agent is necessary when chronic outpatient infusion is being considered. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Precipitating Factors&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;23&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that patients admitted with ADHF undergo evaluation for the following precipitating factors: atrial fibrillation or other arrhythmias (e.g., atrial flutter, other supraventricular tachycardia or ventricular tachycardia), exacerbation of hypertension, myocardial ischemia/infarction, exacerbation of pulmonary congestion, anemia, thyroid disease, significant drug interactions, and other less common factors. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that every effort be made to use the hospital stay for assessment and improvement of patient adherence via patient and family education and social support services (see the NGC summary of the HFSA guideline &lt;a href=&quot;/content.aspx?id=23904&quot; title=&quot;Guideline #7987&quot;&gt;Disease Management, Advanced Directives, and End-of-Life Care in Heart Failure&lt;/a&gt;. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Hospital Discharge&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;25&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that criteria in Table 5, below, be met before a patient with HF is discharged from the hospital. (Strength of Evidence = C)&#xD;&#xA;    &lt;p&gt;In patients with advanced HF or recurrent admissions for HF, additional criteria listed in Table 5 should be considered. (Strength of Evidence = C)&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 5. Discharge Criteria for Patients With Heart Failure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Discharge Criteria for Patients With HF&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommended for all heart failure (HF) patients&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Exacerbating factors addressed. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Near optimal volume status observed. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Transition from intravenous to oral diuretic successfully completed. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Patient and family education completed, including clear discharge instructions. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Left ventricular ejection fraction (LVEF) documented &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Smoking cessation counseling initiated &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Near optimal pharmacologic therapy achieved, including angiotensin-converting enzyme (ACE) inhibitor and beta blocker (for patients with reduced LVEF), or intolerance documented (see the NGC summaries of the HFSA guidelines &lt;a href=&quot;/content.aspx?id=23903&quot; title=&quot;Guideline #7986&quot;&gt;Heart Failure in Patients with Reduced Ejection Fraction&lt;/a&gt; and &lt;a href=&quot;/content.aspx?id=23907&quot; title=&quot;Guideline #7990&quot;&gt;Evaluation and Management of Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Follow-up clinic visit scheduled, usually for 7 to 10 days &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Should be considered for patients with advanced HF or recurrent admissions for HF&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Oral medication regimen stable for 24 hours &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;No intravenous vasodilator or inotropic agent for 24 hours &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Ambulation before discharge to assess functional capacity after therapy &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Plans for postdischarge management (scale present in home, visiting nurse or telephone follow up generally no longer than 3 days after discharge) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Referral for disease management, if available &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;26&quot;&gt;&#xD;&#xA;    &lt;li&gt;Discharge planning is recommended as part of the management of patients with ADHF. Discharge planning should address the following issues:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Details regarding medication, dietary sodium restriction, and recommended activity level &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Follow-up by phone or clinic visit early after discharge to reassess volume status &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medication and dietary adherence &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Alcohol moderation and smoking cessation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monitoring of body weight, electrolytes and renal function &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consideration of referral for formal disease management (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Hierarchy of Types of Evidence&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Hierarchy of Types of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized, Controlled, Clinical Trials&lt;br /&gt;&#xD;&#xA;            May be assigned based on results of a single methodologically rigorous trial&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Cohort and Case-Control Studies&lt;br /&gt;&#xD;&#xA;            Post hoc, subgroup analysis, and meta-analysis&lt;br /&gt;&#xD;&#xA;            Prospective observational studies or registries&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert Opinion&lt;br /&gt;&#xD;&#xA;            Observational studies &amp;ndash; epidemiologic findings&lt;br /&gt;&#xD;&#xA;            Safety reporting from large-scale use in practice&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Classifying the Strength of the Recommendations&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Part of routine care&lt;br /&gt;&#xD;&#xA;            Exceptions to therapy should be minimized. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Should be considered&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Majority of patients should receive the intervention.&lt;br /&gt;&#xD;&#xA;            Some discretion in application to individual patients should be allowed.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;May be considered&quot; &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Individualization of therapy is indicated.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is not recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Therapeutic intervention should not be used&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Accurate evaluation and appropriate management of patients with acute decompensated heart failure&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Diuretics, inotropes, anticoagulants, morphine, and intravascular catheterization are associated with potential side effects and/or adverse effects, and are described in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Some interventions carry relative or absolute contraindications. These contraindications vary according to the specific intervention and are described in the recommendations and accompanying text of the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;It must be recognized that the evidence supporting recommendations is based largely on population responses that may not always apply to individuals within the population. Therefore, data may support overall benefit of one treatment over another but cannot exclude that some individuals within the population may respond better to the other treatment. Thus, guidelines can best serve as evidence-based recommendations for management, not as mandates for management in every patient. Furthermore, it must be recognized that trial data on which recommendations are based have often been carried out with background therapy not comparable to therapy in current use. Therefore, physician decisions regarding the management of individual patients may not always precisely match the recommendations. A knowledgeable physician who integrates the guidelines with pharmacologic and physiologic insight and knowledge of the individual being treated should provide the best patient management.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The value of a practice guideline is significantly influenced by the scope of its dissemination. The first and second Heart Failure Society of America guidelines were available on the Internet, and thousands of copies were downloaded. The current document will be implemented on the Internet both for file transfer and as a hypertext source of detailed knowledge concerning heart failure.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Slide Presentation" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. Evaluation and management of patients with acute decompensated heart failure: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010 Jun;16(6):e134-56. [145 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="1999 (revised 2010 Jun)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Heart Failure Society of America, Inc - Disease Specific Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Heart Failure Society of America, Inc&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Heart Failure Society of America Guideline Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Guideline Committee Members&lt;/em&gt;: JoAnn Lindenfeld, MD (&lt;em&gt;Chair&lt;/em&gt;); Nancy M. Albert, RN, PhD; John P. Boehmer, MD; Sean P. Collins, MD, MSc; Justin A. Ezekowitz, MBBCh; Michael M. Givertz, MD; Stuart D. Katz, MD; Marc Klapholz, MD; Debra K. Moser, RN, DNSc; Joseph G. Rogers, MD; Randall C. Starling, MD, MPH; William G. Stevenson, MD; W.H. Wilson Tang, MD; John R. Teerlink, MD; Mary N. Walsh, MD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Executive Council&lt;/em&gt;: Douglas L. Mann, MD, President; Inder S. Anand, MD; J. Malcolm O. Arnold, MD; John C. Burnett, Jr., MD; John Chin, MD; Jay N. Cohn, MD; Thomas Force, MD; Barry H. Greenberg, MD; Steven R. Houser, PhD; Mariell L. Jessup, MD; Barry M. Massie, MD; Mandeep R. Mehra, MD; Mariann R. Piano, RN, PhD; Clyde W. Yancy, MD; Michael R. Zile, MD&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Committee members and reviewers from the Executive Council received no direct financial support from the Heart Failure Society of America (HFSA) or any other source for the development of the guideline. Support was provided by the HFSA administrative staff, but the writing of the document was performed on a volunteer basis primarily by the Committee. Financial relationships that might represent conflicts of interest were collected annually from all members of the Guideline Committee and the Executive Council. Current relationships are shown in Appendix C of the &quot;2010 HFSA Guideline Executive Summary&quot; companion document (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail 2006 Feb;12(1):e86-103.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.heartfailureguideline.org/&quot; title=&quot;HFSA Web site&quot;&gt;Heart Failure Society of America, Inc. Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Heart Failure Society of America, Inc., Court International - Suite 240 S, 2550 University Avenue West, Saint Paul, Minnesota 55114; Phone: (651) 642-1633&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Heart Failure Society of America. Executive summary: The 2010 HFSA comprehensive heart failure practice guideline. J Card Fail 2010 Jun. Electronic copies: Available from the &lt;a href=&quot;http://www.onlinejcf.com/article/S1071-9164%2810%2900174-0/fulltext&quot; title=&quot;Journal of Cardiac Failure Web site&quot;&gt;Journal of Cardiac Failure Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heart Failure Society of America. Development and implementation of a comprehensive heart failure practice guideline. J Card Fail 2010 Jun;16(6):e3-6. Electronic copies: Available from the &lt;a href=&quot;http://www.onlinejcf.com/article/S1071-9164%2810%2900174-0/fulltext&quot; title=&quot;Journal of Cardiac Failure Web site&quot;&gt;Journal of Cardiac Failure Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heart Failure Society of America. Conceptualization and working definition of heart failure. J Card Fail 2010 Jun;16(6):e34-7. Electronic copies: Available from the &lt;a href=&quot;http://www.onlinejcf.com/article/S1071-9164%2810%2900174-0/fulltext&quot; title=&quot;Journal of Cardiac Failure Web site&quot;&gt;Journal of Cardiac Failure Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PowerPoint slides. HFSA 2010 comprehensive heart failure guideline. Electronic copies: Available from the &lt;a href=&quot;http://www.heartfailureguideline.org/slide_sets_all_recommendations/42&quot; title=&quot;HFSA Web site&quot;&gt;Heart Failure Society of America, Inc. Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Heart Failure Society of America, Inc., Court International - Suite 240 South, 2550 University Avenue West, Saint Paul, Minnesota 55114; Phone: (651) 642-1633&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on July 31, 2006. The information was verified by the guideline developer on August 10, 2006. This summary was updated by ECRI Institute on July 12, 2007 following the U.S. Food and Drug Administration (FDA) advisory on Troponin-1 Immunoassay. This NGC summary was updated by ECRI Institute on October 18, 2010. The updated information was verified by the guideline developer on November 23, 2010. This summary was updated by ECRI Institute on March 7, 2014 following the U.S. Food and Drug Administration advisory on Low Molecular Weight Heparins.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please direct inquiries to &lt;a href=&quot;mailto:info@hfsa.org&quot;&gt;info@hfsa.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
